A Pfizer Inc. plant in China that was being inspected by Food and Drug Administration regulators in order to ship drugs to the U.S. kept a second set of quality and manufacturing records that didn’t match official ones, according to an FDA review of the facility (bloomberg.
from Pocket http://ift.tt/1Pb5P7y
Aucun commentaire:
Enregistrer un commentaire